Corey W Hunter1, Dawood Sayed2, Timothy Lubenow3, Timothy Davis4, Jonathan Carlson5, Jeffery Rowe6, Ralph Justiz7, Tory McJunkin5, Timothy Deer8, Pankaj Mehta9, Steven Falowski10, Leo Kapural11, Jason Pope12, Nagy Mekhail13. 1. Ainsworth Institute of Pain Management, New York, NY, USA. 2. Department of Anesthesiology, University of Kansas Medical Center, Kansas City, KS, USA. 3. Department of Anesthesiology, Rush University Medical Center, Chicago, IL, USA. 4. Orthopedic Pain Specialists, Santa Monica, CA, USA. 5. Arizona Pain, Glendale, AZ, USA. 6. Main Line Spine, King of Prussia, PA, USA. 7. Oklahoma Pain Physicians, Oklahoma, OK, USA. 8. The Spine and Nerve Center of The Virginias, Charleston, WV, USA. 9. Pain Specialists of Austin, Austin, TX, USA. 10. Department of Neurosurgery, St. Luke's University Health Network, Bethlehem, PA, USA. 11. Department of Anesthesiology | Wake Forest University, School of Medicine, Carolinas Pain Institute, Winston Salem, NC, USA. 12. Evolve Restorative Center, Santa Rosa, CA, USA. 13. Department of Pain Management, Cleveland Clinic, Cleveland, OH, USA.
Abstract
INTRODUCTION: Dorsal root ganglion stimulation (DRGS) is a powerful tool in the treatment of chronic, neuropathic pain. The premise of DRGS is similar to that of conventional spinal cord stimulation (cSCS), however, there is more variability in how it can be utilized. While it is this variability that likely gives it its versatility, DRGS is not as straightforward to implement as cSCS. The purpose of this study was to assess the efficacy of DRGS on a broad number of diagnoses, determine which dorsal root ganglia were associated with better outcomes for particular body parts/diagnoses, and evaluate what factors/parameters were associated with higher rates of trial success. METHODS: This is a physician initiated, multicenter retrospective registry of 217 patients trialed with DRGS. Data were collected via an online questionnaire that assessed specifics regarding the patient's pain, distribution, size, and response to treatment. The data were analyzed to see if there were certain diagnoses and/or parameters that were more or less associated with trial success. RESULTS: DRGS was found to be an effective treatment in all diagnoses evaluated within this study, most of which had statistically significant improvements in pain. The most important predictor of trial success was the amount of painful area covered by paresthesias during the programing phase. The number of leads utilized had a direct and indirect impact on trial success. Pain in the distribution of a specific peripheral nerve responded best and there was no statistical difference based on what body part was being treated. CONCLUSION: DRGS can be an effective treatment for a variety of neuropathic pain syndromes, in addition to CRPS. It is recommended that a minimum of 2 leads should be utilized per area being treated. In addition, this therapy was shown to be equally efficacious in any body part/region so long as the area being treated is focal and not widespread.
INTRODUCTION: Dorsal root ganglion stimulation (DRGS) is a powerful tool in the treatment of chronic, neuropathic pain. The premise of DRGS is similar to that of conventional spinal cord stimulation (cSCS), however, there is more variability in how it can be utilized. While it is this variability that likely gives it its versatility, DRGS is not as straightforward to implement as cSCS. The purpose of this study was to assess the efficacy of DRGS on a broad number of diagnoses, determine which dorsal root ganglia were associated with better outcomes for particular body parts/diagnoses, and evaluate what factors/parameters were associated with higher rates of trial success. METHODS: This is a physician initiated, multicenter retrospective registry of 217 patients trialed with DRGS. Data were collected via an online questionnaire that assessed specifics regarding the patient's pain, distribution, size, and response to treatment. The data were analyzed to see if there were certain diagnoses and/or parameters that were more or less associated with trial success. RESULTS: DRGS was found to be an effective treatment in all diagnoses evaluated within this study, most of which had statistically significant improvements in pain. The most important predictor of trial success was the amount of painful area covered by paresthesias during the programing phase. The number of leads utilized had a direct and indirect impact on trial success. Pain in the distribution of a specific peripheral nerve responded best and there was no statistical difference based on what body part was being treated. CONCLUSION: DRGS can be an effective treatment for a variety of neuropathic pain syndromes, in addition to CRPS. It is recommended that a minimum of 2 leads should be utilized per area being treated. In addition, this therapy was shown to be equally efficacious in any body part/region so long as the area being treated is focal and not widespread.
Authors: Jacob Caylor; Rajiv Reddy; Sopyda Yin; Christina Cui; Mingxiong Huang; Charles Huang; Rao Ramesh; Dewleen G Baker; Alan Simmons; Dmitri Souza; Samer Narouze; Ricardo Vallejo; Imanuel Lerman Journal: Bioelectron Med Date: 2019-06-28
Authors: Corey W Hunter; Timothy R Deer; Mark R Jones; George C Chang Chien; Ryan S D'Souza; Timothy Davis; Erica R Eldon; Michael F Esposito; Johnathan H Goree; Lissa Hewan-Lowe; Jillian A Maloney; Anthony J Mazzola; John S Michels; Annie Layno-Moses; Shachi Patel; Jeanmarie Tari; Jacqueline S Weisbein; Krista A Goulding; Anikar Chhabra; Jeffrey Hassebrock; Chris Wie; Douglas Beall; Dawood Sayed; Natalie Strand Journal: J Pain Res Date: 2022-09-08 Impact factor: 2.832
Authors: R Norman Harden; Candida S McCabe; Andreas Goebel; Michael Massey; Tolga Suvar; Sharon Grieve; Stephen Bruehl Journal: Pain Med Date: 2022-06-10 Impact factor: 3.637
Authors: Dongman Chao; Christina M Mecca; Guoliang Yu; Ian Segel; Michael S Gold; Quinn H Hogan; Bin Pan Journal: Pain Date: 2021-12-01 Impact factor: 6.961
Authors: Thomas M Kinfe; Maria Asif; Krishnan V Chakravarthy; Timothy R Deer; Jeffery M Kramer; Thomas L Yearwood; Rene Hurlemann; Muhammad Sajid Hussain; Susanne Motameny; Prerana Wagle; Peter Nürnberg; Sascha Gravius; Thomas Randau; Nadine Gravius; Shafqat R Chaudhry; Sajjad Muhammad Journal: J Transl Med Date: 2019-06-19 Impact factor: 5.531
Authors: Ajay B Antony; B Carsten Schultheis; Suneil M Jolly; Daniel Bates; Corey W Hunter; Robert M Levy Journal: Pain Med Date: 2019-06-01 Impact factor: 3.750